Your partner in planning
Guide your patients to create an informed family planning roadmap with genetic insights.
Myriad Genetics pioneered expanded carrier screening and our Foresight Carrier Screen is systematically designed to maximize the detection of at-risk couples for a pregnancy affected by inherited conditions. We offer seamless support and services to make it easy to integrate genetic screening into your practice.
This means more of your patients will benefit from valuable information that can make a difference in health outcomes for families.
Have the utmost confidence you aren’t missing couples at risk with the highest published at-risk couple detection rate for serious inherited conditions (1 in 22 couples)1
Unmatched detection rates for the vast majority of genes on our panel (>99% across ethnicities) means you can trust both positive and negative results.
Whether its automated results reporting and tracking, merged reports for couples, or on-demand patient education, our solutions are designed to help the patient through the screening process.
Is this condition mild? Or is it serious (moderate, severe or profound)?
Is this information helpful to patients?
Is this condition common enough to be of value?
With the best technology available, how well can we identify carriers?
30% more pregnancies affected with cystic fibrosis* can be identified using Myriad Women’s Health’s testing methodology. *when compared to a traditional 23 mutation panel
Cystic fibrosis and spinal muscular atrophy
Guidelines-focused set of 14 genes
176 genes associated with serious and prevalent inherited conditions
The Foresight Carrier Screen identifies couples who are at elevated risk of passing inherited conditions to their children. Strict disease inclusion criteria are used to select conditions that are serious, clinically-actionable, and prevalent. These conditions have various outcomes:
There is standard, recommended treatment that is reasonably accessible to most affected individuals. e.g. Phenylalanine hydroxylase deficiency (PKU), Wilson disease, Galactosemia, 21-hydroxylase-deficient congenital adrenal hyperplasia (21-OH CAH).
Decrease in average lifespan of affected individuals. e.g. cystic fibrosis, Tay-Sachs disease, spinal muscular atrophy.
A significant risk of intellectual disability, either with or without standard treatment. e.g. fragile X syndrome, Smith-Lemli-Opitz syndrome, metachromatic leukodystrophy
Diseases are not currently curable and effective treatment options are lacking. e.g. Krabbe disease, Bloom syndrome
Provides a significant advantage over targeted sequencing in identifying carriers.
For prevalent, technically-challenging, difficult-to-sequence genes like 21-hydroxylase-deficient congenital adrenal hyperplasia (21-OH CAH).
With select duplication calling for certain prevalent conditions to further boost sensitivity.
Combines automation with manual investigation to classify variants.
Men and women planning to start a family
Before or during pregnancy
4mL blood, or saliva sample
Results in 2 weeks on average
Full-exon sequencing with panel-wide deletion calling
Myriad offers the following through Myriad Complete to help seamlessly integrate testing and screening into your practice.
We provide resources to help you educate your patients about Myriad products.
We offer a comprehensive program to make genetic products accessible for more of your patients.
We deliver screening and testing results effectively and thoroughly so you can focus on care plans.
We provide consults with our Patient Educators, who are genetic counselors, and are available to answer any questions your patients may have.